# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN-TD
- Date: 2016-01-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked. **S**

## Objective

Hemoglobin: 11.8 g/dL (low); White cell count: 6.2 10*3/uL; Platelets: 268 10*3/uL; Creatinine: 0.82 mg/dL; eGFR (CKD-EPI 2011): 82 mL/min/1.73 m²; Glucose: 94 mg/dL; Hemoglobin A1c: 5.5%; PHQ-2: 1. All results are synthetic.

BP 128/80 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 74.6 kg; BMI 27.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked. Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026) **S**
- Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visit. Guideline: Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026); Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018); Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022); Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020) **S**
- Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each note. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
